These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1477849)

  • 1. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
    Steiger MJ; Stocchi F; Bramante L; Ruggieri S; Quinn NP
    Clin Neuropharmacol; 1992 Dec; 15(6):501-4. PubMed ID: 1477849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
    Steiger MJ; Stocchi F; Carta A; Ruggieri S; Agnoli A; Quinn NP; Marsden CD
    Clin Neuropharmacol; 1991 Jun; 14(3):241-4. PubMed ID: 2070364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
    Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
    Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
    Kleedorfer B; Poewe W
    J Neural Transm Park Dis Dement Sect; 1992; 4(2):173-8. PubMed ID: 1571080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
    Diamond SG; Markham CH; Treciokas LJ
    Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Madopar versus sinemet. A clinical study on their effectiveness.
    Korten JJ; Keyser A; Joosten EM; Gabreëls FJ
    Eur Neurol; 1975; 13(2):65-71. PubMed ID: 1095374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
    Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L
    Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.